​

Eli Lilly and Company (LLY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LLY Stock Forecast

Eli Lilly and Company stock forecast is as follows: an average price target of $1.03K (represents a 33.66% upside from LLY’s last price of $767.76) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.

LLY Price Target

The average price target for Eli Lilly and Company (LLY) is $1.03K based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $1.15K to $856.00. This represents a potential 33.66% upside from LLY's last price of $767.76.

LLY Analyst Ratings

Buy

According to 21 Wall Street analysts, Eli Lilly and Company's rating consensus is 'Buy'. The analyst rating breakdown for LLY stock is 0 'Strong Buy' (0.00%), 21 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Eli Lilly and Company Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Evan David SeigermanBMO Capital$1.01K$829.7421.72%31.55%
Oct 14, 2024Andrew BerensLeerink Partners$990.00$932.066.22%28.95%
Sep 13, 2024Peter VerdultCitigroup$1.06K$935.0213.37%38.06%
Aug 27, 2024Terence FlynnMorgan Stanley$1.11K$957.5115.51%44.06%
Aug 14, 2024Kerry HolfordBerenberg Bank$1.05K$908.0515.63%36.76%
Aug 12, 2024James ShinDeutsche Bank$1.02K$891.6814.95%33.51%
Aug 09, 2024Chris ShibutaniGoldman Sachs$856.00$891.68-4.00%11.49%
Aug 09, 2024Mohit BansalWells Fargo$1.00K$845.3118.30%30.25%
Aug 09, 2024Evan David SeigermanBMO Capital$1.10K$845.3130.25%43.40%
Aug 09, 2024Geoff MeachamBank of America Securities$1.15K$845.3136.04%49.79%
Jul 11, 2024Terence FlynnMorgan Stanley$1.08K$939.7815.24%41.06%
Jul 11, 2024Kerry HolfordBerenberg Bank$1.00K$939.786.41%30.25%
Jul 02, 2024Terence FlynnMorgan Stanley$1.02K$906.1512.89%33.24%
Jun 24, 2024Akash TewariJefferies$1.01K$883.8814.83%32.20%
Jun 06, 2024Akash TewariJefferies$957.00$837.2914.30%24.65%
Jun 03, 2024Geoff MeachamBarclays$913.00$820.3411.30%18.92%
May 30, 2024Chris ShibutaniGoldman Sachs$785.00$818.41-4.08%2.25%
May 23, 2024Akash TewariJefferies$925.00$805.0614.90%20.48%
May 20, 2024Akash TewariJefferies$915.00$770.0018.83%19.18%
May 16, 2024Mohit BansalWells Fargo$875.00$771.1213.47%13.97%
May 14, 2024David ToungArgus Research$840.00$757.7010.86%9.41%
May 01, 2024Evan SeigermanBMO Capital$1.00K$781.1028.15%30.38%
Apr 30, 2024Louise ChenCantor Fitzgerald$885.00$781.1013.30%15.27%
Apr 18, 2024Evan David SeigermanBMO Capital$900.00$748.4020.26%17.22%
Feb 06, 2024James ShinDeutsche Bank$535.00$706.20-24.24%-30.32%
Dec 28, 2023Andrew BaumCitigroup$675.00$581.5116.08%-12.08%
Oct 11, 2023David PhungMorgan Stanley$673.00$601.4911.89%-12.34%
Aug 09, 2023Louise ChenCantor Fitzgerald$630.00$526.4019.68%-17.94%
Aug 09, 2023Terence FlynnMorgan Stanley$617.00$526.4017.21%-19.64%
Feb 03, 2023Wells Fargo$360.00$337.546.65%-53.11%
Feb 03, 2023Morgan Stanley$455.00$330.7037.59%-40.74%
Jan 03, 2023Barclays$400.00$366.719.08%-47.90%
Dec 17, 2022Cowen CowenCowen & Co.$430.00$359.8719.49%-43.99%
Dec 16, 2022Leerink Partners$410.00$360.0113.89%-46.60%
Dec 15, 2022UBS$420.00$363.5015.54%-45.30%
Dec 14, 2022Morgan Stanley$440.00$361.9921.55%-42.69%
Dec 08, 2022Wells Fargo$375.00$370.101.32%-51.16%
Dec 07, 2022Guggenheim$401.00$372.397.68%-47.77%
Dec 06, 2022Morgan Stanley$446.00$368.0121.19%-41.91%
Dec 06, 2022Credit Suisse$400.00$367.748.77%-47.90%
Nov 18, 2022Credit Suisse$395.00$360.779.49%-48.55%
Nov 17, 2022Morgan Stanley$436.00$354.6622.93%-43.21%
Oct 02, 2022Colin Bristow BristowUBS$336.00$323.353.91%-56.24%
Sep 22, 2022Navin JacobUBS$363.00$296.4822.44%-52.72%
Sep 07, 2022Morgan Stanley$412.00$310.9132.51%-46.34%
Sep 06, 2022BMO Capital$396.00$306.3829.25%-48.42%
Jul 08, 2022Morgan Stanley$395.00$327.9520.45%-48.55%
Jul 07, 2022Barclays$355.00$330.157.53%-53.76%
Jun 01, 2022J.P. Morgan$355.00$307.7315.36%-53.76%
May 23, 2022David RisingerLeerink Partners$341.00$302.7612.63%-55.59%
May 09, 2022Navin JacobUBS$293.00$289.231.30%-61.84%
May 08, 2022Evan David SeigermanBMO Capital$358.00$296.9020.58%-53.37%
May 03, 2022Vamil DivanMizuho Securities$356.00$289.5622.95%-53.63%
Apr 30, 2022Mohit BansalWells Fargo$305.00$292.134.41%-60.27%
Apr 29, 2022Morgan Stanley$369.00$293.0225.93%-51.94%
Apr 11, 2022Terence FlynnMorgan Stanley$364.00$308.9617.81%-52.59%
Mar 26, 2022Geoff MeachamBank of America Securities$315.00$289.028.99%-58.97%
Feb 06, 2022Matthew HarrisonMorgan Stanley$265.00$242.279.38%-65.48%
Jan 30, 2022Louise ChenCantor Fitzgerald$335.00$245.1036.68%-56.37%
Jan 04, 2022Mohit BansalWells Fargo$280.00$265.705.38%-63.53%
Jan 03, 2022Aaron GalBernstein$300.00$270.6010.86%-60.93%
Dec 20, 2021Carter GouldBarclays$325.00$262.3823.87%-57.67%
Dec 17, 2021Chris ShibutaniGoldman Sachs$236.00$266.31-11.38%-69.26%
Dec 16, 2021Chris SchottJ.P. Morgan$325.00$277.8816.96%-57.67%
Dec 07, 2021Andrew BaumCitigroup$265.00$244.098.57%-65.48%
Nov 29, 2021Navin JacobUBS$267.00$253.775.21%-65.22%
Sep 21, 2021Seamus FernandezGuggenheim$266.00$228.4716.43%-65.35%
Aug 30, 2021Steve ScalaCowen & Co.$300.00$260.3715.22%-60.93%
Aug 09, 2021David ToungArgus Research$300.00$264.3313.49%-60.93%

The latest Eli Lilly and Company stock forecast, released on Oct 31, 2024 by Evan David Seigerman from BMO Capital, set a price target of $1.01K, which represents a 21.72% increase from the stock price at the time of the forecast ($829.74), and a 31.55% increase from LLY last price ($767.76).

Eli Lilly and Company Price Target by Period

1M3M12M
# Anlaysts-226
Avg Price Target-$1.00K$949.04
Last Closing Price$767.76$767.76$767.76
Upside/Downside-100.00%30.25%23.61%

In the current month, the average price target of Eli Lilly and Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Eli Lilly and Company's last price of $767.76. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024BMO CapitalOutperformOutperformHold
Oct 17, 2024BernsteinOutperformInitialise
Oct 14, 2024Leerink PartnersOutperformOutperformHold
Oct 03, 2024Wells FargoBuyBuyHold
Oct 03, 2024Raymond JamesUnderperformUnderperformHold
Sep 25, 2024Goldman SachsBuyBuyHold
Sep 20, 2024Deutsche BankBuyBuyHold
Sep 13, 2024BMO CapitalOutperformOutperformHold
Sep 09, 2024Wells FargoBuyBuyHold
Sep 09, 2024JefferiesUnderperformUnderperformHold
Aug 27, 2024Deutsche BankBuyBuyHold
Aug 27, 2024Morgan StanleyOverweightOverweightHold
Aug 16, 2024GuggenheimBuyBuyHold
Aug 12, 2024Wells FargoBuyBuyHold
Aug 12, 2024Deutsche BankHoldBuyUpgrade
Aug 09, 2024Wells FargoOverweightOverweightHold
Aug 09, 2024BMO CapitalOutperformOutperformHold
Aug 09, 2024Bank of America SecuritiesBuyBuyHold
Jul 24, 2024JefferiesUnderperformUnderperformHold
Jul 24, 2024Truist FinancialBuyBuyHold
Jul 24, 2024Wolfe ResearchOutperformOutperformHold
Jul 12, 2024UBSBuyBuyHold
Jul 10, 2024BarclaysOverweightOverweightHold
Jul 02, 2024Morgan StanleyOverweightOverweightHold
Jun 24, 2024JefferiesBuyBuyHold
Jun 12, 2024J.P. MorganUnderperformUnderperformHold
Jun 12, 2024Truist FinancialBuyBuyHold
Jun 11, 2024Bank of America SecuritiesBuyBuyHold
Jun 03, 2024BMO CapitalOutperformOutperformHold
Jun 03, 2024BarclaysOverweightOverweightHold
May 30, 2024Goldman SachsNeutralNeutralHold
May 20, 2024JefferiesBuyBuyHold
May 01, 2024Wells FargoOverweightOverweightHold
May 01, 2024BarclaysOverweightOverweightHold
Apr 30, 2024Cantor FitzgeraldOverweightOverweightHold
Apr 18, 2024BMO CapitalOutperformOutperformHold
Apr 17, 2024Cowen & Co.BuyBuyHold
Apr 02, 2024CitigroupBuyBuyHold
Apr 01, 2024Wells FargoBuyBuyHold
Mar 01, 2024Bank of America SecuritiesBuyBuyHold
Mar 01, 2024Wells FargoBuyBuyHold
Feb 07, 2024Bank of America SecuritiesBuyBuyHold
Feb 06, 2024Wells FargoOverweightOverweightHold
Feb 06, 2024CitigroupBuyBuyHold
Feb 06, 2024Morgan StanleyOverweightOverweightHold
Feb 06, 2024Deutsche BankUnderperformHoldInitialise
Jan 23, 2024Morgan StanleyBuyBuyHold
Jan 23, 2024Deutsche BankUnderperformUnderperformHold
Dec 28, 2023CitigroupBuyBuyHold
Dec 21, 2023UBSUnderperformUnderperformHold
Dec 21, 2023Wells FargoBuyBuyHold
Dec 19, 2023Goldman SachsNeutralNeutralHold
Dec 18, 2023Goldman SachsHoldHoldHold
Oct 11, 2023Morgan StanleyOverweightOverweightHold
Oct 06, 2023Bank of America SecuritiesBuyBuyHold
Aug 09, 2023BMO CapitalOutperformOutperformHold
Aug 09, 2023Cantor FitzgeraldOverweightOverweightHold
Jun 02, 2023CFRABuyUpgrade
May 23, 2023Cowen & Co.OutperformOutperformHold
May 04, 2023BMO CapitalOutperformOutperformHold
Apr 28, 2023Credit SuisseOutperformOutperformHold
Mar 13, 2023Wells FargoEqual-WeightOverweightUpgrade
Feb 03, 2023Wells FargoEqual-WeightEqual-WeightHold
Feb 03, 2023Morgan StanleyOverweightOverweightHold
Jan 03, 2023BarclaysOverweightOverweightHold
Dec 16, 2022SVB LeerinkOutperformOutperformHold
Dec 15, 2022UBSBuyBuyHold
Dec 14, 2022Morgan StanleyOverweightOverweightHold
Dec 08, 2022Wells FargoEqual-WeightEqual-WeightHold
Dec 07, 2022GuggenheimBuyBuyHold
Dec 06, 2022Credit SuisseOutperformOutperformHold
Dec 05, 2022Cowen & Co.OutperformOutperformHold
Nov 18, 2022Credit SuisseOutperformInitialise
Nov 17, 2022Morgan StanleyOverweightOverweightHold
Sep 22, 2022UBSNeutralBuyUpgrade
Sep 06, 2022BMO CapitalOutperformOutperformHold
Aug 25, 2022CitigroupBuyBuyHold
Aug 24, 2022Morgan StanleyMixedMixedHold
Jul 08, 2022Morgan StanleyOverweightOverweightHold
Jul 07, 2022BarclaysOverweightOverweightHold
May 23, 2022SVB LeerinkOutperformInitialise
May 16, 2022Mizuho SecuritiesBuyBuyHold
May 09, 2022UBSNeutralNeutralHold
Apr 29, 2022BMO CapitalOutperformOutperformHold
Apr 29, 2022Wells FargoEqual-WeightEqual-WeightHold
Apr 28, 2022Piper SandlerOverweightOverweightHold
Apr 11, 2022Morgan StanleyOverweightOverweightHold
Jan 30, 2022Cantor FitzgeraldOverweightOverweightHold
Jan 10, 2022Wells FargoEqual-WeightEqual-WeightHold
Dec 19, 2021BMO CapitalOutperformOutperformHold
Jul 06, 2021BarclaysOverweightOverweightHold
Jun 27, 2021Cantor FitzgeraldOverweightOverweightHold

Eli Lilly and Company's last stock rating was published by BMO Capital on Nov 18, 2024. The company gave LLY a "Outperform" rating, the same as its previous rate.

Eli Lilly and Company Financial Forecast

Eli Lilly and Company Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue-----------$6.96B$7.30B$6.94B$6.49B$7.81B$8.00B$6.77B$6.74B$6.81B$7.44B$5.74B$5.50B$5.86B$6.11B$5.48B$5.64B$5.09B$5.70B$5.23B
Avg Forecast$16.15B$14.63B$14.30B$13.33B$14.02B$12.10B$9.98B$8.94B$8.95B$8.97B$7.58B$6.86B$7.33B$6.89B$6.85B$7.29B$7.69B$6.64B$6.60B$6.93B$7.27B$5.88B$5.76B$5.49B$5.91B$5.50B$5.58B$5.20B$4.19B$5.12B
High Forecast$16.33B$14.79B$14.46B$13.48B$14.27B$12.14B$9.99B$8.94B$9.20B$9.53B$7.67B$6.94B$7.41B$6.89B$6.85B$7.29B$7.69B$6.64B$6.60B$6.93B$7.27B$5.88B$5.76B$5.49B$5.91B$5.50B$5.58B$5.20B$5.02B$6.15B
Low Forecast$15.76B$14.28B$13.95B$13.01B$13.83B$12.05B$9.98B$8.94B$8.73B$8.29B$7.40B$6.70B$7.16B$6.89B$6.85B$7.29B$7.69B$6.64B$6.60B$6.93B$7.27B$5.88B$5.76B$5.49B$5.91B$5.50B$5.58B$5.20B$3.35B$4.10B
# Analysts1111126347136655511121110993332234710
Surprise %-----------1.01%1.00%1.01%0.95%1.07%1.04%1.02%1.02%0.98%1.02%0.98%0.95%1.07%1.03%1.00%1.01%0.98%1.36%1.02%

Eli Lilly and Company's average Quarter revenue forecast for Jun 23 based on 6 analysts is $7.58B, with a low forecast of $7.40B, and a high forecast of $7.67B. LLY's average Quarter revenue forecast represents a 8.95% increase compared to the company's last Quarter revenue of $6.96B (Mar 23).

Eli Lilly and Company EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
EBITDA---------$-6.07B$-6.09B$1.70B$2.39B$2.40B$2.08B$2.74B$2.37B$1.71B$2.05B$1.91B$2.93B$1.89B$2.06B$2.05B$2.10B$1.80B$1.82B$4.85B$1.93B$494.70M
Avg Forecast$4.88B$4.42B$4.32B$4.03B$4.24B$3.66B$3.02B$2.08B$2.70B$2.71B$2.29B$1.89B$2.57B$2.22B$2.21B$1.72B$2.48B$2.14B$2.13B$2.15B$2.34B$1.89B$1.86B$1.67B$1.91B$1.77B$1.80B$4.78B$1.57B$484.39M
High Forecast$4.93B$4.47B$4.37B$4.07B$4.31B$3.67B$3.02B$2.50B$2.78B$2.88B$2.32B$2.27B$3.09B$2.22B$2.21B$2.06B$2.48B$2.14B$2.13B$2.58B$2.34B$1.89B$1.86B$2.01B$1.91B$1.77B$1.80B$5.74B$1.88B$581.27M
Low Forecast$4.76B$4.31B$4.22B$3.93B$4.18B$3.64B$3.01B$1.67B$2.64B$2.50B$2.24B$1.51B$2.06B$2.22B$2.21B$1.38B$2.48B$2.14B$2.13B$1.72B$2.34B$1.89B$1.86B$1.34B$1.91B$1.77B$1.80B$3.82B$1.25B$387.51M
Surprise %----------2.24%-2.66%0.90%0.93%1.08%0.94%1.59%0.96%0.80%0.96%0.89%1.25%1.00%1.11%1.22%1.10%1.02%1.01%1.02%1.23%1.02%

6 analysts predict LLY's average Quarter EBITDA for Jun 23 to be $2.29B, with a high of $2.32B and a low of $2.24B. This is 34.46% upper than Eli Lilly and Company's previous annual EBITDA (Mar 23) of $1.70B.

Eli Lilly and Company Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
Net Income---------$-57.40M$1.76B$1.34B$1.94B$1.45B$952.50M$1.90B$1.73B$1.11B$1.39B$1.36B$2.12B$1.21B$1.41B$1.46B$1.50B$1.25B$1.33B$4.24B$1.22B$-110.80M
Avg Forecast$2.96B$5.15B$4.96B$4.66B$4.95B$1.29B$2.48B$2.00B$2.08B$-161.94M$1.79B$1.82B$1.88B$1.73B$1.54B$1.66B$2.21B$1.77B$1.71B$1.52B$2.14B$1.55B$1.41B$1.19B$1.38B$1.27B$1.31B$4.18B$991.16M$-108.49M
High Forecast$3.01B$5.22B$5.03B$4.72B$5.03B$1.34B$2.48B$2.41B$2.35B$377.86M$1.82B$2.19B$2.25B$1.73B$1.54B$1.99B$2.21B$1.77B$1.71B$1.82B$2.14B$1.55B$1.41B$1.43B$1.38B$1.27B$1.31B$5.01B$1.19B$-86.79M
Low Forecast$2.87B$4.99B$4.80B$4.51B$4.84B$1.23B$2.48B$1.60B$1.80B$-971.64M$1.73B$1.46B$1.50B$1.73B$1.54B$1.33B$2.21B$1.77B$1.71B$1.22B$2.14B$1.55B$1.41B$952.63M$1.38B$1.27B$1.31B$3.34B$792.93M$-130.19M
Surprise %---------0.35%0.98%0.74%1.03%0.84%0.62%1.15%0.78%0.63%0.81%0.89%0.99%0.78%1.00%1.22%1.09%0.99%1.01%1.02%1.23%1.02%

Eli Lilly and Company's average Quarter net income forecast for Sep 23 is $-161.94M, with a range of $-971.64M to $377.86M. LLY's average Quarter net income forecast represents a -109.18% decrease compared to the company's last Quarter net income of $1.76B (Jun 23).

Eli Lilly and Company SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
SG&A---------$1.80B$1.93B$1.75B$1.64B$1.61B$1.63B$1.56B$1.59B$1.58B$1.69B$1.58B$1.55B$1.57B$2.90B$1.55B$1.70B$1.41B$1.59B$1.52B$1.50B$1.54B
Avg Forecast$3.82B$3.46B$3.39B$3.16B$3.32B$2.86B$2.36B$1.64B$2.12B$2.12B$1.80B$1.49B$1.73B$1.65B$1.64B$1.36B$1.84B$1.59B$1.58B$1.77B$1.74B$1.41B$1.38B$1.27B$1.42B$1.32B$1.34B$1.49B$1.22B$1.51B
High Forecast$3.87B$3.50B$3.42B$3.19B$3.38B$2.88B$2.37B$1.97B$2.18B$2.26B$1.82B$1.79B$2.08B$1.65B$1.64B$1.63B$1.84B$1.59B$1.58B$2.12B$1.74B$1.41B$1.38B$1.52B$1.42B$1.32B$1.34B$1.79B$1.47B$1.82B
Low Forecast$3.73B$3.38B$3.30B$3.08B$3.28B$2.85B$2.36B$1.31B$2.07B$1.96B$1.75B$1.19B$1.38B$1.65B$1.64B$1.09B$1.84B$1.59B$1.58B$1.41B$1.74B$1.41B$1.38B$1.01B$1.42B$1.32B$1.34B$1.20B$976.99M$1.21B
Surprise %---------0.85%1.07%1.17%0.95%0.98%0.99%1.15%0.86%0.99%1.07%0.89%0.89%1.12%2.10%1.22%1.20%1.07%1.19%1.02%1.23%1.02%

Eli Lilly and Company's average Quarter SG&A projection for Dec 23 is $2.12B, based on 7 Wall Street analysts, with a range of $2.07B to $2.18B. The forecast indicates a 17.44% rise compared to LLY last annual SG&A of $1.80B (Sep 23).

Eli Lilly and Company EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
EPS---------$-0.06$1.96$1.49$2.04$1.61$1.06$2.11$1.81$1.16$1.53$1.41$2.21$1.26$1.48$1.52$1.56$1.31$1.37$4.33$1.16$-0.10
Avg Forecast$3.27$5.69$5.48$5.14$5.47$1.42$2.74$2.47$2.30$-0.18$1.98$1.73$1.78$1.91$1.70$2.29$2.45$1.96$1.89$2.12$2.37$1.71$1.56$1.48$1.52$1.40$1.45$1.31$0.92$0.94
High Forecast$3.32$5.77$5.56$5.22$5.56$1.48$2.74$2.47$2.59$0.42$2.01$1.75$1.87$1.91$1.70$2.29$2.45$1.96$1.89$2.12$2.37$1.71$1.56$1.48$1.52$1.40$1.45$1.31$1.10$1.13
Low Forecast$3.17$5.51$5.31$4.98$5.35$1.36$2.74$2.46$1.99$-1.07$1.92$1.67$1.70$1.91$1.70$2.29$2.45$1.96$1.89$2.12$2.37$1.71$1.56$1.48$1.52$1.40$1.45$1.31$0.74$0.75
Surprise %---------0.36%0.99%0.86%1.14%0.84%0.62%0.92%0.74%0.59%0.81%0.67%0.93%0.74%0.95%1.03%1.03%0.93%0.95%3.31%1.26%-0.11%

According to 13 Wall Street analysts, Eli Lilly and Company's projected average Quarter EPS for Sep 23 is $-0.18, with a low estimate of $-1.07 and a high estimate of $0.42. This represents a -109.13% decrease compared to LLY previous annual EPS of $1.96 (Jun 23).

Eli Lilly and Company Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MRKMerck$100.06$135.8335.75%Buy
LLYEli Lilly and Company$778.62$1.03K31.80%Buy
AMGNAmgen$265.95$338.2227.17%Buy
PFEPfizer$26.43$32.8324.21%Hold
ABBVAbbVie$175.38$211.2020.42%Buy
JNJJohnson & Johnson$146.41$175.1319.62%Buy
GILDGilead Sciences$92.80$87.30-5.93%Buy
BMYBristol-Myers Squibb Company$57.65$50.50-12.40%Hold

LLY Forecast FAQ

Is Eli Lilly and Company a good buy?

Yes, according to 21 Wall Street analysts, Eli Lilly and Company (LLY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 21 'Buy' recommendations, accounting for 100.00% of LLY's total ratings.

What is LLY's price target?

Eli Lilly and Company (LLY) average price target is $1.03K with a range of $856 to $1.15K, implying a 33.66% from its last price of $767.76. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Eli Lilly and Company stock go up soon?

According to Wall Street analysts' prediction for LLY stock, the company can go up by 33.66% (from the last price of $767.76 to the average price target of $1.03K), up by 49.79% based on the highest stock price target, and up by 11.49% based on the lowest stock price target.

Can Eli Lilly and Company stock reach $1.2K?

LLY's average twelve months analyst stock price target of $1.03K does not support the claim that Eli Lilly and Company can reach $1.2K in the near future.

What are Eli Lilly and Company's analysts' financial forecasts?

Eli Lilly and Company's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $45.04B (high $45.34B, low $44.8B), average EBITDA is $12.99B (high $13.5B, low $12.5B), average net income is $10.72B (high $11.26B, low $10.16B), average SG&A $10.19B (high $10.59B, low $9.8B), and average EPS is $12.1 (high $12.25, low $11.92). LLY's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $58.41B (high $59.06B, low $57B), average EBITDA is $17.65B (high $17.85B, low $17.22B), average net income is $17.73B (high $17.99B, low $17.17B), average SG&A $13.83B (high $13.99B, low $13.5B), and average EPS is $19.59 (high $19.87, low $18.97).

Did the LLY's actual financial results beat the analysts' financial forecasts?

Based on Eli Lilly and Company's last annual report (Dec 2022), the company's revenue was $28.54B, beating the average analysts forecast of $28.36B by 0.65%. Apple's EBITDA was $9.43B, beating the average prediction of $8.72B by 8.19%. The company's net income was $6.24B, missing the average estimation of $6.8B by -8.17%. Apple's SG&A was $6.44B, beating the average forecast of $6.38B by 1.00%. Lastly, the company's EPS was $6.93, missing the average prediction of $7.69 by -9.88%. In terms of the last quarterly report (Mar 2023), Eli Lilly and Company's revenue was $6.96B, beating the average analysts' forecast of $6.86B by 1.41%. The company's EBITDA was $1.7B, missing the average prediction of $1.89B by -9.95%. Eli Lilly and Company's net income was $1.34B, missing the average estimation of $1.82B by -26.21%. The company's SG&A was $1.75B, beating the average forecast of $1.49B by 17.23%. Lastly, the company's EPS was $1.49, missing the average prediction of $1.73 by -13.66%